Abstract
The RS assay is a validated test used to guide treatment decisions in ER+ HER2-negative early-stage BC. We compared RS distribution and expression of the single genes/gene groups within this assay between mBRCA1/2 carriers ER+ HER2-negative BC pts vs the general BC pt population undergoing RS testing.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
